MedTrace Logo

The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury

NCT04340921 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-04-21

No results posted yet for this study

Summary

COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.

Conditions

  • Cardiovascular Disease Acute
  • Cardiomyopathies
  • COVID

Interventions

BIOLOGICAL

COVID-19 exposure

Observation only

Sponsors & Collaborators

  • Queen Mary University of London

    collaborator OTHER

  • Barts & The London NHS Trust

    lead OTHER

Principal Investigators

  • Sam (Saidi) Mohiddin, MD · Barts & The London NHS Trust

  • Federica Marelli-Berg, PhD · Queen Mary University of London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-14
Primary Completion
2023-04-14
Completion
2023-04-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04340921 on ClinicalTrials.gov